STAAR Surgical Company, a leader in the development, manufacturing, and marketing of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia, has entered into a strategic partnership with SharpeVision, a premier ophthalmology group operating clinics in Seattle, Chicago, and Austin. Together, they aim to promote EVO ICL lenses as the preferred choice for individuals seeking freedom from glasses and contact lenses.

The collaboration involves joint efforts in marketing and education to increase awareness about EVO ICL, with a specific focus on expanding access to these lenses for qualified patients across SharpeVision clinics. Additionally, STAAR Surgical will provide support for practice development and clinical aspects. The initial phase of the partnership includes an annual target purchase of 1,000 ICL units, representing approximately 25% of the group’s refractive procedure volume.

The EVO ICL lens offers a permanent solution for vision correction without the need for corneal tissue removal. It also provides the option for removal by a doctor if desired, offering patients flexibility for the future while eliminating the inconveniences of glasses and contact lenses. This collaboration addresses the limitations associated with LASIK and PRK laser vision correction surgeries, such as postoperative ocular surface dryness and corneal weakening/ectasia.

With proven clinical benefits for patients in the U.S. with refractive errors of -3.0 diopters and above, the EVO ICL serves as a flexible and hassle-free alternative to traditional vision correction methods. This partnership represents a significant advancement in expanding the accessibility and impact of EVO ICL technology in the field of ophthalmology.

Source: businesswire.com

 

 

 

Report Abuse